Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

Article de journal

Auteurs / Editeurs

Domaines de Recherche

Détails sur la publication

Liste des auteurs: Sckell A
Editeur: Wiley: 12 months
Année de publication: 1999
Numéro du volume: 83
Numéro de publication: 3
Page d'accueil: 393
Dernière page: 400
Nombre de pages: 8
ISSN: 0020-7136
Languages: Anglais-Royaume-Uni (EN-GB)


The identification of tumor-associated antigens has led to increased
interest in vaccination strategies to treat and/or prevent cancer. This
study examined the feasibility of active-specific immunotherapy against
the breast- tumor antigen HER-2/neu using a HER-2/neu transgenic
(rNeu-TG) mouse model, rNeu-TG mice develop spontaneous breast tumors
after pregnancy, indicating that they fail to mount an effective immune
response against rNeu. Allogeneic fibroblasts expressing HER-2/neu were
used as a cell-based vaccine. Vaccination induced a rNeu-specific
anti-tumor immune response that prevented tumor formation of
transplanted breast-tumor cells, and also protected mice from
spontaneous tumor formation. Both T-cell-mediated and humoral immune
responses were detectable in vaccinated mice. Vaccination also protected
tumor-bearing mice from a challenge with cell suspensions isolated from
spontaneous tumors, indicating that rNeu-TG mice are not tolerant to
rNeu, even after spontaneous tumor formation. However, established
spontaneous tumors themselves were never affected. This observation
correlated with T- cell infiltrations in the injected but not in the
established spontaneous tumor. Thus, allogeneic fibroblasts are
efficient vaccine vectors to prime a specific immune response against an
over-expressed tumor antigen. Moreover, our results suggest striking
differences in the immunological requirements for the rejection of an
established w a transplanted tumor.


Pas d'articles correspondants trouvés.


Pas d'articles correspondants trouvés.

Dernière mise à jour le 2019-13-08 à 00:15